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SUMMARY
TheDNAmethylation regulatorsDNMT3A andTET2 are recurrentlymutated in hematological disorders. Despite possessing antagonistic
biochemical activities, loss-of-function murine models show overlapping phenotypes in terms of increased hematopoietic stem cell
(HSC) fitness. Here, we directly compared the effects of these mutations on hematopoietic progenitor function and disease initiation.
In contrast to Dnmt3a-null HSCs, which possess limitless self-renewal in vivo, Tet2-null HSCs unexpectedly exhaust at the same rate as
control HSCs in serial transplantation assays despite an initial increase in self-renewal. Moreover, loss of Tet2more acutely sensitizes he-
matopoietic cells to the addition of a common co-operatingmutation (Flt3ITD) than loss ofDnmt3a, which is associatedwith amore rapid
expansion of committed progenitor cells. The effect of Tet2mutation manifests more profound myeloid lineage skewing in committed
hematopoietic progenitor cells rather than long-termHSCs.Molecular characterization revealed divergent transcriptomes and chromatin
accessibility underlying these functional differences.
INTRODUCTION
Hematopoiesis is a hierarchywith hematopoietic stem cells
(HSCs) at the apex (Orkin and Zon, 2008). Tasked with self-
renewal to replenish the stem cell pool, and differentiation
to maintain blood production, HSCs must possess func-
tional integrity for the lifetime of an individual. Somatic
mutations acquired during aging can adversely affect this
balance, resulting in hematologic disorders. Two alleles
recurrently mutated in blood diseases are the epigenetic
regulators DNA methyltransferase 3 alpha (DNMT3A) and
tet methylcytosine dioxygenase 2 (TET2) (Cancer Genome
Atlas Research Network, 2013). Tumor evolution analysis
suggests that these mutations are established in HSCs of
these patients (Abelson et al., 2018; Shlush et al., 2014).
In addition, variants in DNMT3A and TET2 are the most
prevalent events associated with clonal hematopoiesis
(CH), where pathogenic mutations are found in the blood
of elderly people lacking overt disease (Buscarlet et al.,
2017; Genovese et al., 2014; Jaiswal et al., 2014; Xie et al.,
2014). These data suggest that DNMT3A and TET2 muta-
tions confer fitness advantages to HSCs.
Despite similarities in disease phenotypes, DNMT3A and
TET2 possess antagonistic biochemical activity. DNMT3A
catalyzes additionofmethylgroups toDNAforming5-meth-
ylcytosine (Okano et al., 1999), while TET2 promotes DNA
demethylation by oxidizing themethyl group to 5-hydroxy-
methylcytosine (Koh et al., 2011). Each mutation alters the
DNA methylome in a predictable manner. In patients with
acute myeloid leukemia (AML), DNMT3A mutations yield
mild hypomethylation of the genome (Spencer et al.,
2017), while TET2 mutations result in hypermethylation
(Figueroa et al., 2010). However, loss of function of either
enzyme inmurine hematopoietic progenitors paradoxically
results in similar altered function, including a competitive
advantage of mutant cells (Celik et al., 2015; Challen et al.,
2012, 2014; Li et al., 2011; Moran-Crusio et al., 2011). The
mechanisms contributing to increased fitness of DNMT3A-
and TET2-mutant HSCs remain largely undefined. The goal
of this study was to directly compare loss-of-function effects
of Dnmt3a and Tet2 at the HSC level through functional as-
says and molecular profiling.
RESULTS
Loss of Dnmt3a and Tet2 Enhances Self-Renewal in
HSCs to Different Degrees
To directly compare the effects of Dnmt3a and Tet2 loss of
function on HSC fate, we performed parallel competitive
HSC transplants. Floxed Dnmt3a (Kaneda et al., 2004) or
Tet2 (Moran-Crusio et al., 2011) mice were crossed with
Mx1-Cre (Kuhn et al., 1995). Treatment with polyinosinic:-
polycytidylic acid (pI:pC) created conditional knockout
mice (Dnmt3a-KOMx1 and Tet2-KOMx1). Mx1-Cre;Dnm-
t3a+/+;Tet2+/+ mice (ControlMx1) were similarly treated with
pI:pC. Eight weeks after pI:pC, 200 HSCs (Lineage c-Kit+
Sca-1+ CD48 CD150+) were transplanted with 2.5 3 105
whole bone marrow (WBM) competitor into wild-type
mice (Figure 1A). No differences were noted in HSC abun-
dance indonormice (Figure S1A).Bloodanalysis (Figure S1B)
revealed significantly higher contribution to all major
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hematopoietic lineages from Tet2-KOMx1 HSCs compared
with control andDnmt3a-KOMx1HSCs in primary recipients
(Figure 1B). In the bone marrow (BM) 18 weeks post-trans-
plant (Figure S1C), the abundance of bothmutantHSC pop-
ulationswas2-foldhigher thanControlMx1HSCs (Figure1B).
Loss of Dnmt3a confers HSCs with unlimited self-renewal
(Jeong et al., 2018). To test if Tet2-KOMx1 HSCs possess the
same ability, serial competitiveHSC transplantationwas per-
formed. Two hundred donor-derived (CD45.2+) HSCs were
purified from primary recipients and transferred to second-
ary recipients with 2.53 105 fresh (CD45.1+)WBM compet-
itor.Tet2-KOMx1HSCsmaintained significantlyhigher blood
production (Figure 1C), and donor-derived HSCs were
increased elevated in recipients of both mutant HSC
genotypes (Figure 1C). When examining other progenitor
populations (Figure S1D), donor-derived multipotent
progenitor 1 ([MPP1] Lineage c-Kit+ Sca-1+ CD48
CD150) and MPP3 (Lineage c-Kit+ Sca-1+ CD48+
A
ControlMx1
Tet2-KOMx1
Dnmt3a - KOMx1
pI:pC x 6
250K WBM
(CD45.1)
200 HSCs
(CD45.2)
200 HSCs 200 HSCs
250K WBM
(CD45.1)
250K WBM
(CD45.1)
Primary Tx Secondary Tx Tertiary Tx
HSC 
Quantification
B D
E
****
*
* **** ****
**
**
0
0.02
0.04
0.06
*
****
********
***
*
0
10
20
30
D
on
or
-D
er
iv
ed
 H
S
C
 
Fr
eq
ue
nc
y 
(%
 o
f L
iv
e 
B
M
)
D
on
or
-D
er
iv
ed
 H
S
C
s 
/ m
ou
se
 
(2
 fe
m
ur
s,
 2
 ti
bi
as
 - 
x1
03
)
ControlMx1 Tet2-KOMx1Dnmt3a -KOMx1
16
 W
ee
k 
D
on
or
-D
er
iv
ed
 
C
hi
m
er
is
m
 (%
C
D
45
.2
+  c
el
ls
)
***
****
Myeloid B cells T cells
*
*
0
25
50
75
100
Myeloid B cells T cells
* ***
**
**
****
* p=0.0641
Myeloid B cells T cells
*
D
on
or
-D
er
iv
ed
 P
er
ip
he
ra
l B
lo
od
E
ng
ra
ftm
en
t (
%
C
D
45
.2
+  c
el
ls
)
0
25
50
75
100
4 8 12 16
**
*
**
**
4 8 12 16
**
**
**
* **
* **
*
Primary Tx Secondary Tx Tertiary Tx
4 8 12 16
**
** **
*
ControlMx1
Tet2-KOMx1
Dnmt3a -KOMx1
0.0
0.2
0.4
0.6
0.8
1.0
ControlMx1
Tet2-KOMx1
Dnmt3a -KOMx1
Differentiation Quotient
1o Tx 2o Tx 3o Tx
C
D
45
.2
+  H
S
C
s 
/ 
20
0 
dn
oo
r H
S
C
s
0
20
40
60
**
**
Self-renewal Quotient
**
**
1o Tx 2o Tx 3o Tx
C
D
45
.2
+  W
B
C
 (p
er
 ?L
 
bl
oo
d)
 / 
C
D
45
.2
+  H
S
C
**
***
*
C
Weeks Post-Transplant
F
Figure 1. Loss of Dnmt3a and Tet2 Enhance
Self-Renewal in HSCs to Different Degrees
(A) HSC serial transplantation schematic.
In descending column order—contribution of
200 ControlMx1, Dnmt3a-KOMx1 (3aKO), and
Tet2-KOMx1 (T2KO) HSCs to peripheral blood,
lineage chimerism, HSC frequency, and HSC
number in (B) primary (CNT n = 28; 3aKO
n = 24; T2KO n = 22), (C) secondary (CNT
n = 27; 3aKO n = 19; T2KO n = 21), and (D)
tertiary (CNT n = 33; 3aKO n = 23; T2KO n = 19)
transplants. (E) Self-renewal and (F) differ-
entiation quotients of indicated HSC geno-
types after each transplant. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.001.
Mean ± SEM is shown.
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CD150) populations were significantly increased in Tet2-
KOMx1 secondary recipients (Figures S1E and S1F). However,
after tertiary transplant, Tet2-KOMx1 HSCs surprisingly
exhausted to similar levels as control HSCs (Figure 1D).
The ratio of donor-derived HSCs to 200 input HSCs (‘‘self-
renewal quotient’’) quantifies the average self-renewal of a
single test HSC (Challen et al., 2012). Dnmt3a-KOMx1 and
Tet2-KOMx1 HSCs both possess greater self-renewal on a
per-HSC basis than control HSCs after primary transplant
(Figure 1E). But the self-renewal quotient of Tet2-KOMx1
HSCs overlaps with ControlMx1 HSCs at the end of tertiary
transplant, in contrast to Dnmt3a-KOMx1 HSCs (Figure 1E).
When examining the differentiation capacities of HSCs
(16-week WBC count multiplied by percentage of donor-
derivedperipheralbloodcells at16weeksdividedbythe total
number of test HSCs, or the ‘‘differentiation quotient’’) both
Dnmt3a-KOMx1 and Tet2-KOMx1 HSCs display a reduced dif-
ferentiation output on a per-HSC basis (Figure 1F).
Tet2 and Dnmt3a Loss of Function Divergently
Influence Rate of Transformation from Same Co-
operating Mutation
To compare functional contribution of Dnmt3a and Tet2
loss of function with leukemogenesis, we crossed Flt3 inter-
nal tandem duplication (Flt3ITD) knockin mice (Lee et al.,
2007) to Vav-Cre;Dnmt3afl/fl or Vav-Cre;Tet2fl/fl mice
(Dnmt3a-KOVav and Tet2-KOVav). Flt3ITD mutation signifi-
cantly decreased time to morbidity in both genetic back-
grounds, but the magnitude varied. Median survival in a
Tet2-deficient background decreased 5.2-fold with
expression of Flt3ITD, whereas survival of Dnmt3a-KOVav
mice only decreased 1.5-fold (Figure 2A). Both Dnmt3a-
KOVavFlt3ITD/+ and Tet2-KOVavFlt3ITD/+ mice presented
with leukocytosis (Figure 2B), anemia, splenomegaly
(Figure S2A), and AML (Figure 2C). A proportion of
Dnmt3a-KOVavFlt3ITD/+ mice developed mixed phenotype
acute leukemia, consistent with the role of Dnmt3a as a
T cell leukemia tumor suppressor (Kramer et al., 2017).
Dnmt3a-KOVav mice without Flt3ITD predominantly devel-
oped BM failure resembling myelodysplastic syndromes,
whereas most Tet2-KOVav mice developed myeloprolifera-
tive disorders or myeloproliferative neoplasms.
Analysis of BM progenitors in moribund mice revealed
significant expansion of the MPP3 population in Flt3ITD
mice (Figure 2D). Flt3ITD depleted HSCs such that even
the enhanced self-renewal of Dnmt3a-KOVav could not
rescue (Figure 2E). The synergism betweenTet2 loss of func-
tion and Flt3ITD alleles in promoting MPP3 expansion was
already detectable in the BM of young adult mice lacking
overt disease (Figure 2F), associated with leukocytosis (Fig-
ure 2G), myeloproliferation (Figures 2H and S2B), spleno-
megaly (Figures 2I and 2J), and lymphoid depletion (Fig-
ure S2C). Even though FLT3ITD mutations co-occur in
patients with AML with both DNMT3A and TET2 muta-
tions (Cancer Genome Atlas Research Network, 2013),
the synergism in Tet2-KOVavFlt3ITD/+ mice show that
founding mutations in Dnmt3a and Tet2 have disparate
sensitivities to the same co-operating mutation.
Tet2 Mutation Does Not Impart Ectopic Self-Renewal
to Hematopoietic Progenitors, but Loss of Dnmt3a
Confers Phenotypic Plasticity
Expansionof theMPP3population inmoribundFlt3ITDmice
implicated this BM compartment as the disease-initiating
cell population. To test this, 250 MPP3 from young mice
were transplantedwith2.53105wild-typeWBMcompetitor
cells. Regardless of genotype, donor-derived cells were barely
detectable in the blood (Figure S3A) and failed to engraft the
BM and generate disease (data not shown). This demon-
strates that neither loss of Dnmt3a nor Tet2, alone or com-
bined with Flt3ITD, imparts self-renewal properties to
normally non-self-renewing progenitors.
Transplantation of ControlVav, Tet2-KOVav, and Dnmt3a-
KOVav WBM against equal numbers of wild-type BM
confirmed the competitive advantage of unfractionated
Tet2-KOVav BM (Figures S3B and S3C). But as Tet2-KOMx1
HSC self-renewal was eventually exhausted (Figure 1D),
this suggested that a non-HSC progenitor population
may contribute to the observed myeloid dominance from
Tet2-mutant BM. We performed competitive transplant of
Figure 2. Tet2 and Dnmt3a Loss of Function Divergently Influence Rate of Transformation from Same Co-operating Mutation
(A) Kaplan-Meier plot comparing time to morbidity between ControlVav (n = 30), Flt3ITD (n = 20), Dnmt3a-KOVav (n = 15), Tet2-KOVav
(n = 11), Dnmt3a-KOVavFlt3ITD (n = 16), and Tet2-KOVavFlt3ITD (n = 12) mice.
(B) White blood cell count of day 600 ControlVav and moribund mice of indicated genotypes.
(C) Pathological diagnosis of moribund mice.
(D) Representative flow cytometry plots of moribund mice demonstrating expansion of MPP3 (red box) and depletion of HSCs (purple box)
in Flt3ITD genotypes.
(E) Frequency and number of HSCs and MPP3 in moribund mice.
(F–J) (F) Frequency and number of HSCs and MPP3 in 8-week-old ControlVav (n = 18), Flt3ITD (n = 14), Dnmt3a-KOVav (n = 18), Dnmt3a-
KOVavFlt3ITD (n = 10), Tet2-KOVav (n = 15), and Tet2-KOVavFlt3ITD (n = 9) mice. Pathological analysis of young adult mice showing (G) WBC
counts, (H) peripheral blood myeloid cells, (I) spleen weights, and (J) spleen myeloid cells. *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.001. Mean ± SEM is shown.
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Figure 3. Tet2 Mutation Does Not Impart Ectopic Self-Renewal to Hematopoietic Progenitors, but Skews Myeloid Differentiation
of Committed Progenitor Cells
(A) Donor-derived peripheral blood cells and 16-week lineage chimerism in recipients of 200 MPP1 from ControlVav (n = 8), Dnmt3a-KOVav
(n = 7), and Tet2-KOVav (n = 5) mice.
(B) Frequency of MPP1-transplanted mice with >1% donor-derived engraftment in myeloid, B cell, and T cell lineages.
(legend continued on next page)
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200 MPP1 (Figure 3A). Peripheral blood analysis revealed
long-term tri-lineage engraftment among recipients of
both Dnmt3a-KOVav and Tet2-KOVav MPP1 (Figure 3B),
whereas all recipients of ControlVav MPP1 had <1%
donor-derived myeloid cells (Celik et al., 2018). From BM
analysis (Figure 3C), Tet2-KOVav MPP1 failed to self-renew
but Dnmt3a-KOVav MPP1 reconstituted the BM MPP1
compartment (Figure 3D). Surprisingly, we also observed
donor-derived HSCs in all Dnmt3a-KOVav MPP1 recipients
(Figures 3C and 3D). Loss ofDnmt3amaybestow epigenetic
plasticity between the HSC andMPP1 compartments, rein-
forcing the importance of Dnmt3a in maintenance of
hematopoietic cell type identity.
Loss of Tet2 Skews Myeloid Differentiation of
Committed Progenitor Cells
As increasedmyeloid output fromTet2-deficient HSCs could
not be attributed to differences in self-renewal, proliferation
(Figure S3D), or apoptosis (Figure S3E), wehypothesized that
epigenetic dysfunction may skew myeloid differentiation
fromhematopoietic progenitors. To quantify this, in vitro as-
says were performed with purified HSCs, MPP1, and MPP3.
In methylcellulose, all genotypes initially had the same
number of colonies (Figure S3F). Both mutant alleles sus-
tained some colony-forming potential in MPP1 and MPP3
in serial plating. A third passage distinguished Dnmt3a-KO-
Vav HSCs with a significant increase in colony number (Fig-
ure S3F). The lack of serial replating of Tet2-KOVav MPP3
in vitro was consistent with engraftment failure in vivo.
Progenitors were then cultured with hematopoietic cyto-
kines in OP9 stroma-coated plates. After 2 weeks, analysis
withmyeloidmarkersGr-1 andCD11b (Mac-1) showedclear
differences from Tet2-KOVav progenitors. A Gr-1hi popula-
tion was lacking while Gr-1mid and Gr-1lo populations were
more prevalent (Figure S3G). Further immunophenotyping
(Figure 3E) revealed a disproportionate production of
myeloidcells. LossofTet2 increaseddendritic cell andmacro-
phage production from MPP1 and MPP3 at the expense of
neutrophils (Figure 3F). This suggests that the primary func-
tionofTet2mutations inhematopoietic progenitors is not to
increase self-renewal, but rather skewmyeloid output.
Dnmt3a and Tet2 Loss of Function Alter
Hematopoietic Progenitor Function through Distinct
Molecular Mechanisms
Transcriptional profiling was performed to elucidate mech-
anisms underlying the functional differences between
HSCs over serial transplantation. Unfortunately, the dimi-
nution of ControlMx1 and Tet2-KOMx1 HSCs at later trans-
plant stages permitted only two replicates (Table S1). As a
supplement, HSCs were purified from ControlVav,
Dnmt3a-KOVav, and Tet2-KOVav adult mice (Table S2). The
gene expression profiles of ControlVav and Dnmt3a-KOVav
HSCs were remarkably similar (Figure S4A), despite their
functional differences. Tet2-KOVav HSCs showed a larger
dysregulated expression signature (Figure 4A). Of the 24
genes downregulated in Dnmt3a-KOVav HSCs, 11 also
showed significant repression in Tet2-KOVav HSCs (Fig-
ure 4B). Genes, such as Mki67 and Hmgb2 also showed
consistent downregulation in the mutant HSCs across
serial transplant (Figure S4B) andmay contribute to the dif-
ferentiation block. A total of 62 out of 288 (21.5%) genes
upregulated in Dnmt3a-KOVav HSCs were shared with
Tet2-KOVav HSCs, including jun and Fos, which form the
AP-1 transcription factor complex important in HSC stress
response (Mallaney et al., 2019). Transcriptional analysis
was also performed on ControlVav and Tet2-KOVav MPP3
from young adult mice to understand the myeloid lineage
skewing arising from loss of Tet2. Although there were
fewer differentially expressed genes (DEGs) than the HSC
comparison of the same genotypes (Figure 4C), gene set
enrichment analysis revealed significantly dysregulated
gene sets (Figure 4D). Themajor difference was diminished
nuclear factor kB signaling in Tet2-KOVav MPP3 (Figure 4E).
ATAC sequencing (ATAC-seq) was performed to examine
chromatin accessibility in HSCs, MPP1, and MPP3. The
most striking difference was global reduction of open chro-
matin inTet2-KOVav HSCs andMPP1 (Figure 4F), consistent
with the function of Tet2 in promoting DNA demethyla-
tion at enhancers (Sardina et al., 2018; Wang et al., 2018).
However, Tet2-KOVav MPP3 recovered chromatin accessi-
bility above ControlVav levels, including addition of new
peaks at 800 hematopoietic enhancers and 1,232 pro-
moters enriched for myeloid function (Figure S4C).
The chromatin landscape of ControlVav andDnmt3a-KOVav
progenitors revealed fewer differences. A multi-dimen-
sional scaling analysis showed the Dnmt3a-KOVav MPP1
cluster closer to HSCs than ControlVav MPP1 (Figure 4G),
supporting the notion of a reduced epigenetic barrier be-
tween these cell types in the absence of Dnmt3a.Moreover,
areas with reduced chromatin accessibility in Dnmt3a-KO-
VavMPP1 (Table S3) involved genes involved in hematopoi-
etic lineage specification, such as Fli1 and Izkf1, whichmay
contribute to the differentiation block.
(C) Representative plots showing donor-derived MPP1 and HSCs in recipients of Dnmt3a-KOVav MPP1.
(D) Frequency and chimerism of donor-derived HSCs and MPP1 in recipients of 200 MPP1.
(E) Representative immunophenotyping of in vitro differentiated progenitor cells.
(F) Immunophenotypic populations produced via in vitro differentiation of progenitor cells from ControlVav and Tet2-KOVav mice (n = 4 per
population of each genotype). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001. Mean ± SEM is shown.
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Figure 4. Dnmt3a and Tet2 Loss of Function Alter Hematopoietic Progenitor Function through Distinct Molecular Mechanisms
(A) Principal-component analysis plot of gene expression in ControlVav HSCs (n = 3) and MPP3 (n = 4), Dnmt3a-KOVav HSCs (n = 3), and
Tet2-KOVav HSCs (n = 4) and MPP3 (n = 4).
(B) Venn diagrams displaying DEG overlap in Dnmt3a-KOVav and Tet2-KOVav HSCs compared with ControlVav HSCs.
(C) Heatmaps displaying DEGs (p < 0.05, fold-change >1 or <1) between ControlVav and Tet2-KOVav HSCs and MPP3.
(D) Gene set enrichment analysis showing differentially regulated pathways between ControlVav and Tet2-KOVav MPP3.
(E) Gene score enrichment plot of ‘‘Hallmark TNFa Signaling via NFkB’’ gene set in Tet2-KOVav MPP3.
(legend continued on next page)
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DISCUSSION
Somatic mutations in DNMT3A and TET2 comprise
approximately 70% of all variants in age-related CH. The
persistence of these mutations (Young et al., 2016) coupled
with their recurrence in blood malignancies of diverse lin-
eages suggests a stem cell origin. Mouse model studies sug-
gest a similar increase inHSC self-renewal after inactivation
of both genes. Previous studies demonstrate a competitive
advantage for Tet2-deficient cells in BM transplantation as-
says (Li et al., 2011; Moran-Crusio et al., 2011). Although
this is assumed to be due to enhanced HSC self-renewal,
these experiments have been performed with WBM or
less pure populations of progenitors. Our results using
highly purified HSCs show that Tet2 loss of function
modestly increased self-renewal on a per-HSC basis during
early passages of transplantation, but this effect was tran-
sient and Tet2-deficient HSCs exhausted to comparable
levels as control HSCs after tertiary transplant. This is in
stark contrast to Dnmt3a-deficient HSCs which show no
signs of self-renewal diminution. Moreover, by transplant-
ing defined numbers of HSCs, our quantification shows
that, on a per-cell basis, Tet2-mutant HSCs show a similar
differentiation deficit as Dnmt3a-mutant HSCs. This was
not anticipated given the high peripheral blood chimerism
observed from transplantation of Tet2-null WBM, particu-
larly in the myeloid lineage. Rather, our data suggest that
increased myeloid output results from skewed differentia-
tion in progenitors lacking Tet2. More open chromatin at
enhancers of pro-myeloid differentiation genes in
Tet2-KOVav MPP3 may contribute to this phenotype.
Our data are instructive for how these mutations are
propagated in humans with chromatin immunoprecipita-
tion. DNMT3A mutations are highly specific for the HSC
compartment, with the increase in self-renewal potential
allowing these mutations to be efficiently propagated in
humans with age. The fact that the mutations do not cause
massive transcriptional changes still allows these mutant
HSCs to function as effective stem cells, but with greater
self-renewal to withstand external stresses that would nor-
mally force HSC depletion. Although Tet2 loss of function
does not induce ectopic self-renewal in either normal or
malignant progenitor cells, this mutation alters the
myeloid output of progenitors and potentially sensitizes
them to secondary mutations that further drive prolifera-
tion. This aligns with evidence in humans showing that
these mutations do not have equal potential. Analysis of
individuals with CH shows DNMT3A mutations can be
found in all blood lineages, whereas TET2 mutations are
often absent from Tcells (Buscarlet et al., 2018), supportive
of differential effects on progenitor lineage differentiation.
Our data suggest amodel forTET2-mutant CHwhereby the
mutation is acquired in HSCs, but the functional effects of
myeloproliferation are realized by more downstream
progenitors.
EXPERIMENTAL PROCEDURES
Detailed methods are provided in Supplemental Information.
Mice and Transplantation
The Institutional Animal Care and Use Committee at Washington
University approved all animal procedures. All mice were C57Bl/6
background. Dnmt3afl/fl (Kaneda et al., 2004) and Tet2fl/fl (Moran-
Crusio et al., 2011) mice were crossed to Flt3ITD (Lee et al., 2007),
Vav-Cre (Georgiades et al., 2002), and Mx1-Cre (Kuhn et al., 1995)
strains. To induceMx1-Cre, six doses (300 mg) of polyinosinic:poly-
cytidylic acid (pI:pC; Sigma, no. p1530) were administered every
48 h via intraperitoneal injection to 8-week-old mice. Mice were
allowed to recover for 6 weeks after the last pI:pC injection before
sacrifice for HSC purification. Transplant recipients (C57Bl/6
CD45.1, The Jackson Laboratory strain no. 002014), received a
split dose of irradiation (10.5 Gy) 4 h apart. Cells were trans-
planted via retro-orbital injection.
RNA-Seq Data, Quality Control, and Analysis
Reads were aligned with STAR v.2.5.4b with Gencode release M20
(GRCm38.p6) genome assembly. Unambiguous read counts were
calculated by HTSEQ-count. Data were imported into Noiseq
v.2.28.0 for differential gene expression analysis with TMM
normalization and batch correction. RNA-seq data are available
under GEO GSE139911.
ATAC-Seq
Open chromatin was profiled via the Omni-ATACmethod (Corces
et al., 2017). Readswere aligned tomm10with BWAmemv.0.7.17.
Duplicates were removed with Picard tools MarkDuplicates v.2.0.1
and bams were processed with snakePipes v.1.3.1. Differential
chromatin accessibility was assessed using Rsubread v.1.34.7 and
EdgeR v.3.26.8. Peaks were intersected with enhancers using bed-
tools v.2.25.0. Bigwig tracks and heatmaps were created via deep-
Tools2 v.3.3.1. ATAC-seq data are available underGEOGSE139911.
Statistics
Student’s t test, and one- and two-way ANOVAwere used for statis-
tical comparisons where appropriate. Kruskal-Wallis test was used
for non-normal data. Survival curves were analyzed using a
Mantel-Cox log rank test. Significance is indicated using the
(F) ATAC-seq heatmaps from ControlVav, Dnmt3a-KOVav, and Tet2-KOVav mice. Signals displayed are peaks 1 kb up- and downstream of
transcription start sites of protein coding genes.
(G) Multi-dimensional scaling plot with distances approximating the largest log2 fold-changes in the top 500 peaks between ATAC-seq
samples.
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following convention: *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001. All graphs represent mean ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
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Supplemental Experimental Procedures 
 
Mice and transplantation 
The Institutional Animal Care and Use Committee at Washington University approved all animal 
procedures. All mice were C57Bl/6 background. Dnmt3afl/fl (Kaneda et al., 2004) and Tet2fl/fl (Moran-Crusio et 
al., 2011) mice were crossed to Flt3ITD (Lee et al., 2007), Vav-Cre (Georgiades et al., 2002) and Mx1-Cre (Kuhn 
et al., 1995) strains. To induce Mx1-Cre, six doses (300ug) of polyinosinic:polycytidylic acid (pI:pC; Sigma 
#p1530) were administered every 48-hours via intraperitoneal injection to eight-week old mice.  Mice were 
allowed to recover for six-weeks after the last pI:pC injection prior to sacrifice for donor HSC purification (total 
age of donor mice = four-months). Equal numbers of male and female mice were pooled for HSC purification for 
transplantation. Bone marrow transplant recipient mice (C57Bl/6 CD45.1, The Jackson Laboratory strain 
#002014), received a split dose of lethal irradiation (10.5 Gy) ~4 hours apart.  Cells were transplanted via retro-
orbital injection. For HSC (CD45.2+ Lineage- c-Kit+ Sca-1+ CD48- CD150+) and MPP1 (CD45.2+ Lineage- c-Kit+ 
Sca-1+ CD48- CD150-) transplants, 200 donor cells were purified by flow cytometry and transplanted into lethally 
irradiated CD45.1 recipients with 2.5x105 wild-type CD45.1 WBM support. MPP3 (CD45.2+ Lineage- c-Kit+ Sca-
1+ CD48+ CD150-) transplant recipients received 250 purified cells in addition to the WBM support.  For 
secondary transplants, donor-derived HSCs were purified from primary recipients and transplanted (200 per 
mouse) with 2.5x105 fresh CD45.1 WBM support into secondary recipients.  Tertiary transplants were performed 
in a similar manner.  Genotyping primers are presented in the table below; 
 
Gene Primer Sequence 
Vav-CRE Forward AGATGCCAGGACATCAGGAACCTG 
Vav-CRE Reverse ATCAGCCACACCAGACACAGAGATC 
Mx-1 CRE Forward CTGGGGATTGCTTATAACACCC 
Mx-1 CRE Reverse TCATCAGCTACACCAGAGACGG 
Tet2 Forward AAGAATTGCTACAGGCCTGC 
Tet2 Reverse TTCTTTAGCCCTTGCTGAGC 
Dnmt3a Forward ATCACATTACCTTTGTCCTCCCAGATCCAG 
Dnmt3a Reverse AGGCTGTCTGCATCGGACAGTGAGTGGTG 
 
Flow Cytometry  
Cells were stained in Hanks Balanced Salt Solution (HBSS, Corning #21021CV) containing Pen/Strep 
(100Units/mL, Fisher Scientific #MT30002CI), HEPES (10M, Life Technologies #15630080) and Serum Plus II 
(2%, Sigma #14009C) at a density of 1.0x108/mL. Staining was performed for >20 minutes at 4oC with the 
following anti-mouse antibodies (1:100 dilutions, all from BioLegend unless stated otherwise): CD45.1 (clone 
Ostrander et al. 
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A20, #110706), CD45.2 (clone 104, #84208), B220 (clone A20, #103212), Gr-1 (clone RB6-8C5, #108416), Mac-
1 (clone M1/70, #101216), CD3e (clone 145-2C11, #100312), Ter119 (clone TER-119, #116223), NK1.1 (clone 
PK136, eBiosciences #13-5941-85), CD48 (clone HM48-1, #103424), CD150 (clone TC15-12F12.2, #115904), 
c-Kit (clone 2B8, #84158), Sca-1 (clone E13-161.7, #122512), CD11c (clone N418, eBiosciences #13-0114-82), 
CD5 (clone 53-7.3, #100622), CD19 (clone 6D5, #115520), F4/80 (clone BM8, #123133), Ly6C (clone HK1.4, 
#128005), Ly6G (clone 1A8, #127627).  Negative controls used to set gates were established using fluorescence 
minus one (FMO) tubes for a parameter of interest, or isotype staining controls.                        
WBM was isolated from tibias, femurs, and iliac crests and combined for calculating total WBM from each 
mouse. Hematopoietic progenitor cells were purified via flow cytometry from enriched WBM using anti-mouse 
CD117-conjugated microbeads (Miltenyi Biotec #130-091-224). WBM was incubated on ice with microbeads for 
30 minutes and enriched using the AutoMACS Pro Separator (Miltenyi Biotec #130-092-545). Post-enrichment, 
samples were stained with antibodies for cell sorting. Peripheral blood from transplant recipients was analyzed 
for test (CD45.2) and competitor (CD45.1) contributions to hematopoietic lineages by FACS using the two CD45 
isoform antibodies as well as myeloid (Gr-1+ and Mac-1+), B-cell (B220+) and T-cell (CD3e+) antibodies. 
 
Methocult Colony Forming Assays 
Colony forming assays were performed by plating 100 HSCs, MPP1, and MPP3, or 1.0x104 WBM cells 
into a 6-well plate with 2mL of methocellulose-based medium (MethoCult M3434, Stemcell Technologies 
#03434). Colonies were scored on day nine for the first plating. Serial colony formation potential was determined 
by passaging 10,000 cells isolated from the previous plating into new 6-well plates with 2mL of Methocult M3434. 
Colonies were scored on day 7 for serial passages.  
 
Differentiation Assay 
Myeloid differentiation potential was assessed by plating 225 HSCs, MPP1, or MPP3 onto OP9 stromal 
cells in MEM-Alpha (Gibco # LS12571063) supplemented with Pen-Strep (100 units/mL), mSCF (50 ng/mL), 
mFlt3L (10 ng/mL), and mIL-3 (10 ng/mL), mGM-CSF (10 ng/mL), mM-CSF (10 ng/mL), and mG-CSF  (10 
ng/mL). Cells were analyzed via flow cytometry for immunophenotyping: dendritic cells (NK1.1-, CD5-, CD19-, 
Mac-1+, CD11c+), neutrophils (NK1.1-, CD5-, CD19-, Mac-1+, CD11c-, Ly6G+, Ly6C+), monocytes (NK1.1-, 
CD5-, CD19-, Mac-1+, CD11c-, Ly6G-, Ly6C+, F4/80-), macrophages (NK1.1-, CD5-, CD19-, Mac-1+, CD11c-, 
Ly6G-, Ly6C+, F4/80+). 
 
RNA-SEQ data, quality control and analysis 
HSCs and MPP3 were purified from four biological replicates (pooled WBM from two male and two female 
mice). A NucleoSpin RNA XS kit (Macherey-Nagel #740902.250) was used to isolate RNA. Library preparation, 
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sequencing, and alignment was performed by the Genome Technology Access Center (Washington University). 
The SMARTer Ultra Low RNA kit (Clontech) was used to prepare the libraries from 3-5ng of total RNA. 
Sequencing was performed with an Illumina HiSeq-3000. Reads were aligned with STAR (Dobin et al., 2013) 
version 2.5.4b with Gencode release M20 (GRCm38.p6) genome assembly. Unambiguous read counts were 
calculated by HTSEQ-count (Anders et al., 2015) version 0.6.0 with mode “intersection-strict.” Expression data 
were imported into Noiseq v2.28.0 (Tarazona et al., 2015) for differential gene expression analysis with TMM 
normalization and batch correction. Gene set enrichment analysis was performed with fGSEA v1.10.0. Primary 
RNA-SEQ data is available under GEO accession number GSE139911. 
 
ATAC-seq 
Open chromatin was profiled using a modified Omni-ATAC method (Corces et al., 2017).  Briefly, 10,000 
HSCs, MPP1, and MPP3 were sorted by flow cytometry into 500 µL of PBS + 0.2% BSA. Cells were pelleted 
and resuspended in 50 µL of ATAC-RSB buffer with 0.1% NP40, 0.1% Tween-20, and 0.01% digitonin and 
incubated on ice for three minutes. Samples were washed with ATAC-RSB buffer with 0.1% Tween-20 and nuclei 
were pelleted and resuspended in transposition reaction mixture with transposase (Nextera) for 30 minutes at 
37oC and 1000 RPM shaking. DNA was purified using Zymo DNA Clean and Concentrator-5 Kit (Zymo #D4014). 
Libraries were amplified using NEBnext (New England Biolabs) with custom Nextera primers. Cycle number was 
determined with qPCR as previously described. Libraries were purified with Ampure XP beads. Libraries were 
sequenced with an Illumina HiSeq-3000 (PE2X150).  ATAC-seq reads were aligned to mm10 with BWA mem 
v0.7.17. Duplicates were removed with Picard tools MarkDuplicates v2.0.1 and the resulting bams were 
processed with snakePipes v1.3.1 (Bhardwaj et al., 2019) ATAC-seq pipeline. A consensus peak set was derived 
by comparing narrrowPeak files for each replicate and keeping a peak region if present in at least two replicates. 
Differential chromatin accessibility was assessed by downsampling the filtered bam outputs from snakePipes to 
the smallest represented library size and counting the reads that fell into the consensus peaks using Rsubread 
v1.34.7 (Liao et al., 2019). The resulting count matrix was analyzed via EdgeR v3.26.8 (Robinson et al., 2010) 
for differential read counts keeping the starting library size throughout the analysis. Peaks were annotated with 
genomic features using csaw v1.18.0.  Peaks were also intersected with enhancers (Aranda-Orgilles et al., 2016) 
using bedtools v2.25.0.  Bigwig tracks and heatmaps were created through deepTools2 v3.3.1 (Ramirez et al., 
2016). Tracks were visualized with IGV v2.7.2.  Gene ontology analysis was performed with GREAT v4.0.4 
(McLean et al., 2010).  Primary ATAC-seq data is available under GEO accession number GSE139911. 
 
Statistics 
Student t-test, one-way, and two-way ANOVA’s were used for statistical comparisons where appropriate. 
Kruskal-wallis test was used for non-normal data. Survival curves were analyzed using a Mantel-Cox logrank 
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test. Significance is indicated using the following convention: *p <0.05, **p <0.01, ***p <0.001, ****p <0.0001.  All 
graphs represent mean ± S.E.M.   
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Figure S1: Loss of Dnmt3a and Tet2 Enhance Self-Renewal in HSCs to Different Degrees, Related to 
Figure 1. 
(A) Frequency and absolute numbers of HSCs from adult Mx1-Cre mouse strains six-weeks after the last pIpC 
injection at time of sacrifice for HSC purification for transplantation.  (B) Flow cytometry plots of representative 
gating for peripheral blood analysis. (C) Representative flow cytometry plots of BM from recipient mice defining 
donor-derived HSCs.  (D) Flow cytometry plots of representative gating for MPP1 and MPP3 populations. 
Frequency of donor-derived (E) MPP1 and (F) MPP3 from transplantation of ControlMx1 (CNT), Dnmt3a-KOMx1 
(3aKO), and Tet2-KOMx1 (T2KO) HSCs at 18-weeks following primary (CNT n=28; 3aKO n=24; T2KO n=22), 
secondary (CNT n=27; 3aKO n=19; T2KO n=21), and tertiary (CNT n=33; 3aKO n=23; T2KO n=19) transplants. 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001. Mean ± S.E.M. values are shown. 
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Figure S2: Tet2 and Dnmt3a loss-of-function divergently influence hematopoietic progenitor cells, 
Related to Figure 2. 
(A) Platelet counts, RBC, hemoglobin, and spleen weights of moribund mice. (B) BM myeloid, B-cell, and T-cell 
distribution of 8-week old mice from indicated genotypes. (C) Proportion of B-cells and T-cells in peripheral blood 
and spleens of mice from eight-week old ControlVav (n=18), Flt3ITD (n=14), Dnmt3a-KOVav (n=18), Dnmt3a-
KOVavFlt3ITD (n=10), Tet2-KOVav (n=15), and Tet2-KOVavFlt3ITD (n=9) mice. **p < 0.01, ***p < 0.001, ****p < 0.001. 
Mean ± S.E.M. values are shown. 
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Figure S3: Tet2 Mutation Does Not Impart Ectopic Self-Renewal to Hematopoietic Progenitors But Skews 
Myeloid Differentiation of Committed Progenitor Cells, Related to Figure 3. 
(A) Donor-derived peripheral blood cells and 16-week lineage chimerism in recipients of 250 MPP3 from 
ControlVav (n=8), Flt3ITD (n=5), Dnmt3a-KOVav (n=5), Tet2-KOVav (n=7), Dnmt3a-KOVavFlt3ITD (n=3), or Tet2-
KOVavFlt3ITD (n=7) mice. (B) Donor-derived peripheral blood cells and (C) 16-week lineage chimerism in recipients 
of 5.0x105 BM from ControlVav (n=5), Dnmt3a-KOVav (n=5) and Tet2-KOVav (n=4) mice competed against 5.0x105 
CD45.1 BM. (D) Percentage of quiescent (G0) HSCs and MPP3 in ControlVav (n=5) and Tet2-KOVav (n=3) mice 
by Ki67 / DAPI flow cytometry. (E) Percentage of apoptotic HSCs and MPP3 in ControlVav (n=5) and Tet2-KOVav 
(n=3) mice by AnnexinV flow cytometry. (F) Colony counts from serial replating assays (n=6-10 per genotype). 
(G) Representative flow cytometry plots of in vitro differentiated cells from ControlVav and Tet2-KOVav mice. 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001. Mean ± S.E.M. values are shown. 
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Figure S4: Dnmt3a and Tet2 Loss of Function Alter Hematopoietic Progenitor Function Through Distinct 
Molecular Mechanisms, Related to Figure 4. 
(A) Heatmap displaying differentially expressed genes (p<0.05, fold-change > 1 or < -1) between ControlVav and 
Dnmt3a-KOVav HSCs. (B) Transcriptional profile of genes commonly downregulated in Dnmt3a-KOVav and Tet2-
KOVav HSCs across serial transplant (TX) of Mx1-Cre HSCs. (C) Gene ontology analysis of the genomic regions 
that gained chromatin accessibility in Tet2-KOVav MPP3 using GREAT. Enrichment of the top 20 GO biological 
processes are displayed. 
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Supplemental Tables 
 
Table S1:  Gene expression in HSCs across serial transplantation.  Related to Figure 4. 
Normalized RNA-seq gene expression values (counts per million = cpm) of ControlMx1, Dnmt3a-KOMx1, and Tet2-
KOMx1 HSCs across serial competitive transplantation. 
 
Table S2:  Gene expression in HSCs and MPP3s.  Related to Figure 4. 
Normalized RNA-seq gene expression values (transcripts per million = tpm) of ControlVav, Dnmt3a-KOVav, and 
Tet2-KOVav HSCs and MPP3s. 
  
Table S3:  Open chromatin profiling in HSCs, MPP1s and MPP3s.  Related to Figure 4. 
Differential regions of open chromatin from ATAC-seq analysis of ControlVav, Dnmt3a-KOVav, and Tet2-KOVav 
HSCs, MPP1s and MPP3s. 
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